Welcome to our dedicated page for Park Ha Biological Technology Co., Ltd. SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Ha Biological Technology Co., Ltd.'s SEC filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries that sell Park Ha skincare and cosmetic products in China. Current reports on Form 6-K cover Nasdaq listing compliance, board changes, shareholder voting matters and amendments to its memorandum and articles.
The company's filings also describe its capital structure, including Class A ordinary shares, Class B ordinary shares with higher voting rights, warrants issued in public offerings, securities purchase agreements, placement agency arrangements and Form F-1 registration statement disclosures. These records connect financing activity and share-capital matters to BYAH's public-company governance and reporting obligations.
Park Ha Biological Technology Co., Ltd. (BYAH) completed a Regulation S private investment in public equity (PIPE), selling 1,080,000 Class A ordinary shares at $2.75 per share to non-U.S. investors for aggregate gross proceeds of about $2,970,000 before expenses. Purchasers also received warrants to purchase 1,845,452 Class A ordinary shares, exercisable immediately for five years at an exercise price of $1.10 per share, with each warrant exercisable for two and one half Class A ordinary shares and subject to customary anti-dilution adjustments. The transaction closed on September 11, 2026, and the company intends to use net proceeds for general working capital and corporate purposes. The securities were issued in offshore transactions under Regulation S and are restricted from transfer to U.S. persons absent registration or an applicable exemption.
Park Ha Biological Technology Co., Ltd. (BYAH) replaced its independent registered public accounting firm, terminating WWC, P.C. on September 1, 2026 and appointing HTL INTERNATIONAL, LLC as the new auditor for its financial statements.
The company reports that WWC’s audit reports for the fiscal years ended October 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications, and that there were no disagreements or reportable events with WWC through the dismissal date. The change in auditor was recommended and approved by the Audit Committee and the Board of Directors.
Park Ha Biological Technology Co., Ltd. received a Schedule 13G filing indicating that Motovance Holdings Limited and Li Wang each beneficially own 422,500 Class A Ordinary Shares, representing 9.7% of the Class A Ordinary Shares. Each reporting person has sole voting and dispositive power over these shares. The percentage interest is calculated based on 2,297,902 Class A Ordinary Shares outstanding following a reverse stock split effective August 6, 2026, plus 2,040,000 Class A Ordinary Shares issued upon exercise of a warrant after that date.
Park Ha Biological Technology Co., Ltd. received a Schedule 13G reporting passive ownership in its Class A Ordinary Shares, par value $0.008 per share. The filing is by Fusen Advertising Design Limited and Hao Meng, who are treated as joint reporting persons.
The filing states that Fusen Advertising Design Limited beneficially owns 425,500 Class A Ordinary Shares and Hao Meng beneficially owns 422,500 Class A Ordinary Shares, each representing 9.8% of the class. These amounts include 260,000 shares issuable upon exercise of warrants that are exercisable within 60 days. The ownership percentages are calculated based on 2,297,902 Class A Ordinary Shares outstanding following a reverse stock split effective August 6, 2026, plus 2,000,000 Class A Ordinary Shares underlying another warrant exercisable within 60 days. Both reporting persons have sole voting and dispositive power over their reported holdings.
Park Ha Biological Technology Co., Ltd. has a Schedule 13G reporting that PINNACLE INTERNATIONAL HOLDING LIMITED and Yajie Ma each beneficially own 325,000 Class A Ordinary Shares, or 7.6% of this class. Each reporting person has sole voting and dispositive power over these shares. The holdings include 200,000 Class A Ordinary Shares issuable upon exercise of warrants that are exercisable within 60 days. The ownership percentage is calculated based on 2,297,902 Class A Ordinary Shares outstanding following a reverse stock split effective August 6, 2026, plus 2,000,000 Class A Ordinary Shares underlying a warrant exercisable within 60 days.
Nexera Technology Company Limited and Jie Cao report beneficial ownership of Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares. Each reporting person beneficially owns 390,000 Class A Ordinary Shares, including 240,000 shares issuable upon exercise of warrants within 60 days. This represents 9.1% of the Class A Ordinary Shares, based on 2,297,902 shares outstanding following a reverse stock split effective August 6, 2026, plus 2,000,000 shares underlying a warrant that is exercisable within 60 days. Each reporting person has sole voting and dispositive power over these 390,000 shares.
Park Ha Biological Technology Co., Ltd. had a Schedule 13G filed by Velociti Group Limited and Chunxin Xia, identified as the reporting persons for the company’s Class A Ordinary Shares, par value $0.008 per share. Each reporting person has sole voting and dispositive power over 422,500 Class A Ordinary Shares and no shared power. This amount includes 260,000 shares issuable upon exercise of warrants within 60 days. The reported holdings represent 9.8% of the Class A Ordinary Shares. The ownership percentage is calculated based on 2,297,902 Class A Ordinary Shares outstanding following a reverse stock split effective August 6, 2026, plus 2,000,000 Class A Ordinary Shares underlying a warrant exercisable within 60 days.
Park Ha Biological Technology Co., Ltd. received a Schedule 13G filing from Rove Trading Co., Limited and Yingying Guo, disclosing significant holdings of its Class A Ordinary Shares, par value $0.008 per share, CUSIP G6925R128.
Each reporting person is shown with 422,500 Class A Ordinary Shares of beneficial ownership and a 9.8% stake in the class, including 260,000 shares issuable upon exercise of warrants within 60 days. The ownership percentage is calculated based on 2,297,902 Class A Ordinary Shares outstanding following a reverse stock split effective August 6, 2026, plus 2,000,000 shares underlying a warrant that is also exercisable within 60 days. Both report sole voting and dispositive power over their respective positions.
Peverel Summit Holdings Limited and Qi Meng report beneficial ownership of Class A Ordinary Shares of Park Ha Biological Technology Co., Ltd. Each reporting person holds or controls 422,500 Class A Ordinary Shares, representing 9.8% of the class.
The reported holdings include 260,000 Class A Ordinary Shares issuable upon exercise of warrants that are exercisable within 60 days. The ownership percentage is calculated based on 2,297,902 Class A Ordinary Shares outstanding after a reverse stock split effective August 6, 2026, plus 2,000,000 shares underlying a warrant exercisable within 60 days.
Park Ha Biological Technology Co., Ltd. has a significant shareholder reported on a Schedule 13G. Corin Global Partners Holdings Limited and its reporting person, Ng Yee Loon, together report beneficial ownership of 422,500 Class A ordinary shares, or 9.8% of the class. These holdings include 260,000 shares issuable upon exercise of warrants within 60 days, giving the reporting persons sole voting and dispositive power over all reported shares. The ownership percentage is calculated using 2,297,902 Class A ordinary shares outstanding after an August 6, 2026 reverse stock split, plus 2,000,000 shares underlying another warrant exercisable within 60 days.